Advertisement

Topics

PhaseBio licenses MedImmune's ticagrelor reversal agent

14:40 EST 29 Nov 2017 | Elsevier Business Intelligence

MedImmune LLC granted PhaseBio Pharmaceuticals Inc. exclusive global rights to MEDI2452 (renamed PB2452), which is entering P...

Original Article: PhaseBio licenses MedImmune's ticagrelor reversal agent

NEXT ARTICLE

More From BioPortfolio on "PhaseBio licenses MedImmune's ticagrelor reversal agent"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...